GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

ClinicalKey

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell #LungCancer (HARMONi-6): interim ove

A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting

<![CDATA[Ateganosine Combo Demonstrates Disease Control in Third-Line NSCLC]]>

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospit

An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

Conditions : NSCLC Interventions : Drug: HS-10504； midazolam Sponsors : Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Phase 1 trial of ABBV-706 in 288 patients with advanced solid tumors reveals potential in SCLC: 240 on monotherapy, 124 with RR-SCLC. PMID:4